| Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer’s disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid … Y Wang, Y Sun, Y Guo, Z Wang, L Huang, X Li Journal of Enzyme Inhibition and Medicinal Chemistry 31 (3), 389-397, 2016 | 58 | 2016 |
| Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease CJ Lu, J Hu, Z Wang, S Xie, T Pan, L Huang, X Li MedChemComm 9 (11), 1862-1870, 2018 | 42 | 2018 |
| Therapeutic targeting of FGFR signaling in head and neck cancer Z Wang, KS Anderson The Cancer Journal 28 (5), 354-362, 2022 | 15 | 2022 |
| Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies ME Lidsky, Z Wang, M Lu, A Liu, SD Hsu, SJ McCall, Z Sheng, JA Granek, ... NPJ Precision Oncology 6 (1), 75, 2022 | 14 | 2022 |
| Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy Z Wang, V Muthusamy, DP Petrylak, KS Anderson NPJ Precision Oncology 7 (1), 70, 2023 | 5 | 2023 |
| Exploring APOBEC3A and APOBEC3B substrate specificity and their role in HPV positive head and neck cancer C Papini, Z Wang, SN Kudalkar, TP Schrank, S Tang, T Sasaki, C Wu, ... Iscience 25 (10), 2022 | 5 | 2022 |
| One more powerful weapon to fight bladder cancer in our anti-cancer arsenal: a promising synergistic combination of FGFR and HDAC targeted therapy Z Wang Cancer, 2023 | 1 | 2023 |
| Tackling FGFR Fusion-Positive Cancers With a Novel Synergistic Combination of FGFR and HDAC Inhibitors Z Wang Yale University, 2023 | | 2023 |
